MedTrace Logo

Dexmedetomidine for Improved Pain Relief and Recovery in Spine Surgery

NCT06685081 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2024-11-12

No results posted yet for this study

Summary

Chronic low back pain (CLBP) is a prevalent condition causing significant pain, disability, and reduced quality of life. While various treatments like exercise, NSAIDs, and spinal manipulation are recommended, their effectiveness is limited. Epidural steroid injections can provide short-term relief but may not be cost-effective and have associated risks.

Dexmedetomidine (DXM) is a selective α2-adrenergic agonist with analgesic properties. It has been used as an adjuvant to anesthetics and analgesics to enhance pain relief and reduce opioid consumption. Using DXM in conjunction with local anesthetics for regional blocks has shown promising results in improving analgesia and functional outcomes.

Conditions

  • Pain, Postoperative

Interventions

DRUG

Dexmedetomidine

Dexmedetomidine was injected in dose of 0.25 µg/kg

DRUG

Dexmedetomidine

Dexmedetomidine was injected in dose of 0.5 µg/kg

DRUG

Dexmedetomidine

Dexmedetomidine was injected in dose of 0.75 µg/kg

DRUG

Dexmedetomidine

Dexmedetomidine was injected in dose of 1 µg/kg

DRUG

lidocaine and triamcinolone

2 ml of 1.5% lidocaine and 2 ml of triamcinolone was mixed and provided to all patients as epidural injection

Sponsors & Collaborators

  • Menoufia University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
35 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-01
Primary Completion
2024-10-15
Completion
2024-11-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06685081 on ClinicalTrials.gov